Vitamin D and cinacalcet are associated with increased survival in peritoneal dialysis but not with residual renal function preservation
.

Abstract

BACKGROUND:

Active vitamin D and cinacalcet, a treatment for secondary hyperparathyroidism and also with potential anti-inflammatory properties, have been associated with lower risk of death among dialysis patients. Vitamin D has also been described to decrease proteinuria in CKD patients. This study aims to assess the relationship of vitamin D and cinacalcet with survival and residual renal function preservation among peritoneal dialysis patients.

MATERIALS AND METHODS:

In a retrospective peritoneal dialysis cohort of 581 subjects, we assessed if vitamin D and cinacalcet therapy are associated with increased risk of death and residual renal function loss using Kaplan-Meier analysis and Cox proportional hazard analysis.

RESULTS:

Vitamin D treatment was associated with a 56% reduction in the risk of death (HR 0.44, 95% CI 0.28 - 0.67) and cinacalcet also with a 54% lower risk of death (HR 0.46, 95% CI 0.31 - 0.69) in multivariate models adjusting for each other. Hyperphosphatemia (> 6 mg/dL) was associated with an 85% increase in mortality (HR 1.85, 95% CI 1.30 - 2.65). Neither vitamin D (HR 1.04, 95% CI 0.45 - 2.39) nor cinacalcet (HR 0.74, 95% CI 0.45 - 1.20) were associated with a lower risk of anuria.

CONCLUSION:

Vitamin D and cinacalcet therapy was associated with a lower risk of death but not anuria, beyond other known risk factors among peritoneal dialysis patients.
.

• Authors: Susie L Hu, Priyanka Joshi, Mark Kaplan, Judy Lefkovitz, Dominique S Michaud
• Journal: Clinical nephrology (Clin Nephrol) Vol. 90 Issue 5 Pg. 305-312 (Nov 2018) ISSN: 0301-0430 [Print] Germany
• PMID: 29956649 (Publication Type: Journal Article)

Chemical References

• Vitamin D
• Cinacalcet

Topics

• Cinacalcet (adverse effects, therapeutic use)
• Humans
• Hyperphosphatemia
• Peritoneal Dialysis (mortality)
• Renal Insufficiency, Chronic (drug therapy, mortality)
• Retrospective Studies
• Risk Factors
• Vitamin D (adverse effects, therapeutic use)